Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J L MurrayJ U Gutterman

Abstract

Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 to 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE) ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (less than or equal to grade II) in 24 patients with chief side effects being chills (80% of patients), fever (70%), malaise (60%), and nausea (55%). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8 degrees C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P less than .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, beta 2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1 beta were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-i...Continue Reading

Citations

Feb 1, 1990·Cancer Metastasis Reviews·P W WhitworthI J Fidler
Aug 13, 2009·Expert Review of Anticancer Therapy·Paul A Meyers
May 21, 2010·Paediatric Drugs·James E Frampton
Jan 14, 2011·Expert Opinion on Pharmacotherapy·Kosei AndoDominique Heymann
Feb 19, 2011·Sarcoma·Seth M PollackRobin L Jones
Oct 19, 2013·British Journal of Clinical Pharmacology·Karthik VenkatakrishnanAshley Milton
Jun 12, 2018·Journal of Pediatric Hematology/oncology·Nurdan TacyildizGulsan Yavuz
Mar 1, 1992·World Journal of Surgery·I J Fidler
Aug 1, 1993·Cancer Immunology, Immunotherapy : CII·M MaedaE S Kleinerman
Jan 27, 1995·Pharmacy World & Science : PWS·J J BergersI A Bakker-Woudenberg
Jul 1, 2008·Expert Opinion on Medical Diagnostics·Beth A Goins
Oct 19, 2013·British Journal of Clinical Pharmacology·Karthik VenkatakrishnanAshley Milton
Oct 2, 2015·Current Oncology Reports·Melissa BurgessHussein Tawbi
Jul 1, 1994·Cancer Immunology, Immunotherapy : CII·S CaplanY Barenholz
Jan 1, 1994·International Journal of Technology Assessment in Health Care·A C Allison
Sep 30, 1993·International Journal of Cancer. Journal International Du Cancer·E GalligioniS Monfardini
Nov 1, 1993·Cancer Immunology, Immunotherapy : CII·T AsanoE S Kleinerman
Dec 22, 2007·Expert Opinion on Drug Delivery·Steven Dow
Dec 5, 2019·Clinical & Translational Immunology·Matthew E GriffinHoward C Hang
Oct 1, 1994·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·J B Gano, E S Kleinerman
Mar 31, 2012·European Journal of Clinical Pharmacology·Karthik VenkatakrishnanCristina Oliva
Dec 30, 2014·Oncotarget·Lorenzo GalluzziGuido Kroemer
Aug 8, 2018·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Francis ManRafael T M de Rosales
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·B P BarnaS D Deodhar
May 8, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chand KhannaMark Bernstein
Nov 1, 1995·Antimicrobial Agents and Chemotherapy·B PasslickH W Ziegler-Heitbrock

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.